darunavir has been researched along with (5-Chloropyridin-3-yl) 1H-indole-4-carboxylate in 1 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies ((5-Chloropyridin-3-yl) 1H-indole-4-carboxylate) | Trials ((5-Chloropyridin-3-yl) 1H-indole-4-carboxylate) | Recent Studies (post-2010) ((5-Chloropyridin-3-yl) 1H-indole-4-carboxylate) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 6 | 0 | 4 |
| Protein | Taxonomy | darunavir (IC50) | (5-Chloropyridin-3-yl) 1H-indole-4-carboxylate (IC50) |
|---|---|---|---|
| Spike glycoprotein | Betacoronavirus England 1 | 0.03 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 0.03 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 0.03 | |
| Procathepsin L | Homo sapiens (human) | 0.03 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 0.03 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 0.03 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 0.1007 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.1872 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 0.03 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for darunavir and (5-Chloropyridin-3-yl) 1H-indole-4-carboxylate
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |